Stanford Cancer Center

Hematology CRG

Click here to print this page (PDF)

11 June 2015

Acute Myeloid Leukemia (AML)

Elderly

- **Previously Untreated**
  - **Induction Therapy Candidate**
    - **No**
      - **Unfit for Intensive Therapy**
        - **HEM0030** Liposomal Cytarabine +Daunorubicin (CPX-351) in MDS &Non-APL AML at High Risk of Tx-Related Mortality
          PI: Medeiros (Pending)
      - **WBC > 10 K**
        - **HEMAML0021** Phase 1b MLN4924 + Azacitidine in Treatment-Naïve Acute Myelogenous Leukemia >= 60 Years Old
          PI: Coutre Millennium Pharmaceuticals
      - **WBC < 10 K**
        - **HEMAML0034** Phase 1b ABT-199 w/ Azacitidine / Decitabine in Treatment Naïve AML greater than 65 years old
          PI: Medeiros (Pending)
      - **FLT3**
        - **HEMAML0022** Phase II Decitabine in Combo w/ Midostaurin (PKC412) in Newly Diagnosed FLT3-ITD/TKD Positive AML
          PI: Medeiros Stanford
          - → **HEMAML0022-EXT** Extension Midostaurin (PKC412) in FLT3-ITD/TKD Mutated AML in prior Tx with Midostaurin & Decitabine
            Medeiros Stanford
- **Previously Treated**
  - **HEMAML0017** Phase II Temozolomide + Vorinostat in Patients (>60) w/ Newly Diagnosed or Relapse/ Refractory AML
    PI: Medeiros Stanford
  - **Demethylating Agent Failure**
    - **HEM0036** Phase II CPX-351 in AML / Higher Risk MDS Relapsed / Refractory to Prior Tx w/ Hypomethylating Agent
      PI: Medeiros Stanford

KEY

- Pending
- Open for Enrollment
- Observational Study
- Optional Path
- Link Trial Posting
- Enrollment on Hold
- Extension Study

Please mark up a copy using black ink and fax changes to 725-9204